Shanghai Aidu Biotechnology Co., Ltd – Trademark Portfolio

Entity Type: 99

Shanghai Aidu Biotechnology Co., Ltd holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 4 filings in this category. Currently, 4 trademarks are registered. Notable registered marks include REJUEGT, OLEUIMMU, RHODIOREX, and PROFISETIN. The owner is based in Shanghai.

No. 80 Hanxiao Road

Shanghai 200135 , CN

4 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

REJUEGT
REJUEGT
Registered 2024
RHODIOREX
RHODIOREX
Registered 2020
OLEUIMMU
OLEUIMMU
Registered 2020

Trademark Classifications

Shanghai Aidu Biotechnology Co., Ltd's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

1
Chemicals (4 filings)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

Frequently Asked Questions

How many trademarks does Shanghai Aidu Biotechnology Co., Ltd have?

Shanghai Aidu Biotechnology Co., Ltd has 4 U.S. trademarks filed with the USPTO. Of these, 4 registered.

What trademark classes does Shanghai Aidu Biotechnology Co., Ltd file in?

Shanghai Aidu Biotechnology Co., Ltd files trademarks across 1 Nice Classification class. The most active classes are Class 1 (Chemicals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.

What are Shanghai Aidu Biotechnology Co., Ltd's most well-known trademarks?

Shanghai Aidu Biotechnology Co., Ltd's registered trademark portfolio includes well-known marks such as REJUEGT, OLEUIMMU, RHODIOREX, and PROFISETIN. These are among 4 currently registered trademarks in the portfolio.

What is Shanghai Aidu Biotechnology Co., Ltd's trademark registration success rate?

Shanghai Aidu Biotechnology Co., Ltd has a 100% trademark registration rate, with 4 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.